Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
18%
Ph phase_3
3
27%
Ph phase_4
2
18%
Ph phase_1
1
9%
Ph phase_2
3
27%

Phase Distribution

1

Early Stage

3

Mid Stage

5

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
3(27.3%)
Phase 3Large-scale testing
3(27.3%)
Phase 4Post-market surveillance
2(18.2%)
N/ANon-phased studies
2(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(7)
Other(3)

Detailed Status

Completed7
unknown3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (9.1%)
Phase 23 (27.3%)
Phase 33 (27.3%)
Phase 42 (18.2%)
N/A2 (18.2%)

Trials by Status

not_yet_recruiting19%
completed764%
unknown327%

Recent Activity

0 active trials
Showing 5 of 11
not_yet_recruitingnot_applicable

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

NCT06607926
completedphase_3

The Efficacy and Safety of Ta1 for Sepsis

NCT02867267
completedphase_2

Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer

NCT03659578
completedphase_4

Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis

NCT02473406
unknownphase_3

Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff

NCT04320238
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT06607926Not Applicable

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

Not Yet Recruiting
NCT02867267Phase 3

The Efficacy and Safety of Ta1 for Sepsis

Completed
NCT03659578Phase 2

Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer

Completed
NCT02473406Phase 4

Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis

Completed
NCT04320238Phase 3

Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff

Unknown
NCT02883595Phase 4

Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis

Completed
NCT02787447Phase 2

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

Unknown
NCT01031966Phase 2

A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine

Completed
NCT00711620Not Applicable

Efficacy of Thymosin alpha1 for Severe Sepsis

Completed
NCT01178996Phase 3

Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.

Completed
NCT00580450Phase 1

Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11